- Thrixen secures $9.53m funding for point-of-care diagnostic technology, raising capital through 22Health Ventures and Aldevron co-founder John Ballantyne
- Funding will advance development of Thrixen’s novel diagnostic technology platform, replacing antibodies with proprietary assay technology
- Thrixen’s VIBEX rapid multiplex test can distinguish between bacterial and viral infections from a finger prick sample within 10 minutes
- Investment and partnerships aim to improve patient care by enabling faster, more accurate medical decisions at the point of care
- 22Health Ventures to provide access to US market and operational expertise, with co-founder Ara Tavitian joining Thrixen as a board member
Thrixen Secures Funding for Point-of-Care Diagnostic Technology
Thrixen, a medical technology start-up, recently made headlines by securing $9.53m in funding for its innovative point-of-care diagnostic technology. The funding round was co-led by 22Health Ventures, an early-stage health technology venture firm, and Aldevron co-founder John Ballantyne. This significant capital injection will play a crucial role in advancing the development of Thrixen’s novel diagnostic platform that aims to revolutionize the way diagnostic tests are conducted at the point of care.
Revolutionizing Diagnostic Testing at the Point of Care
Thrixen’s proprietary assay technology lies at the heart of its groundbreaking innovation. Unlike traditional diagnostic methods that rely on antibodies, Thrixen’s protein engineering platform has demonstrated an impressive sensitivity of 99.5% in clinical trials. This technology paves the way for the development of the VIBEX rapid multiplex test, which has the capability to differentiate between bacterial and viral infections using a simple finger prick sample in just 10 minutes. By enabling healthcare professionals to make faster and more accurate medical decisions at the point of care, Thrixen’s technology has the potential to significantly improve patient care outcomes.
Impact of the Funding on Thrixen’s Growth
CEO Shavit Clein expressed enthusiasm about the funding’s implications for Thrixen’s growth trajectory. The investment and new partnerships forged through this funding round will play a pivotal role in the company’s ability to develop initial use cases, conduct successful clinical trials, and establish a robust regulatory framework to bring its product to market. The collaboration with 22Health Ventures will not only provide Thrixen with access to the US market but also offer valuable operational expertise and management guidance, with Ara Tavitian, co-founder and managing partner of 22Health Ventures, joining Thrixen as a board member. With the support of existing investors such as Ntuitive and private investors, Thrixen is well-positioned to drive forward its mission of transforming point-of-care diagnostics.
Related Video
Expanding Access to Innovative Healthcare Solutions
Thrixen’s funding success underscores the growing interest and investment in innovative biomedical startups that are focused on improving healthcare outcomes. By developing cutting-edge technology that empowers healthcare professionals to deliver timely and accurate diagnoses at the point of care, Thrixen is poised to make a significant impact in the medical field. The ability to differentiate between bacterial and viral infections swiftly and accurately has the potential to streamline treatment protocols, reduce unnecessary antibiotic use, and ultimately enhance patient care.
Thrixen’s recent funding milestone represents a significant step forward in the advancement of point-of-care diagnostic technology. With a strong focus on innovation, precision, and improving patient outcomes, Thrixen is well-positioned to make a lasting impact in the healthcare industry. As the company continues to develop its novel diagnostic platform, supported by strategic partnerships and investor backing, the future looks promising for the transformation of diagnostic testing at the point of care.
Links to additional Resources: